Wal-Mart is providing customers with a way to safely dispose of unused opioids; Kentucky's governor signs a bill to protect his Medicaid overhaul; Maryland coalition aims to ban price gouging for specialty and brand-name drugs.
Customers who fill opioid prescriptions at Wal-Mart will also receive a way to dispose of the drugs that prevent them from being misused. According to Reuters, customers will be given a packet of powder that they can mix with water and add to their pill bottle to dispose of unused opioids. The power and water mixture creates a biodegradable gel around the pills.
If a court were to strike down Kentucky’s overhaul of Medicaid, which requires able-bodied beneficiaries to work, then Governor Matt Bevin would strip half a million people of their coverage. The executive order Bevin signed would mostly affect adults added to the program after it was expanded under former Governor Steve Beshear, a Democrat, reported Courier Journal. So far, no legal challenge has been brought against Bevin’s overhaul of Medicaid, but several advocacy groups said it likely will be since some changes violate the federal law that establishes Medicaid.
The Maryland Health Care for All! Coalition is aiming to protect certain brand-name drugs from price gouging. AP reported that the coalition is trying to build on the success of a law in 2017 that was the first to prohibit price gouging of generic and off-patent drugs. Some of the drugs being targeted include those for multiple sclerosis, HIV/AIDS, and hepatitis C.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More